West Coast Financial LLC cut its stake in Stryker Co. (NYSE:SYK - Free Report) by 2.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,320 shares of the medical technology company's stock after selling 700 shares during the period. Stryker accounts for approximately 1.4% of West Coast Financial LLC's investment portfolio, making the stock its 13th largest holding. West Coast Financial LLC's holdings in Stryker were worth $12,403,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker during the fourth quarter valued at $25,000. Capital A Wealth Management LLC acquired a new position in shares of Stryker during the fourth quarter valued at $26,000. Rakuten Securities Inc. increased its holdings in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC acquired a new position in shares of Stryker during the fourth quarter valued at $30,000. Finally, BankPlus Trust Department acquired a new position in shares of Stryker during the fourth quarter valued at $33,000. 77.09% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
SYK has been the topic of a number of research analyst reports. Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday, May 5th. The Goldman Sachs Group set a $422.00 target price on Stryker in a research note on Tuesday, March 4th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Roth Mkm raised their target price on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Truist Financial raised their target price on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research note on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $427.30.
Check Out Our Latest Research Report on SYK
Stryker Trading Up 0.0%
Shares of NYSE:SYK traded up $0.19 during midday trading on Thursday, reaching $382.74. The company had a trading volume of 904,802 shares, compared to its average volume of 1,332,627. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The firm has a market cap of $146.09 billion, a price-to-earnings ratio of 49.32, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a fifty day simple moving average of $369.68 and a two-hundred day simple moving average of $376.11.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the company posted $2.50 EPS. Research analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.
Stryker Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio is currently 45.41%.
Insider Buying and Selling
In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.90% of the company's stock.
About Stryker
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Read More
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
